Li Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Li Zhang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Peter R. Kowey
Lankenau Medical Center and Lankenau Institute for Medical Research, Jefferson Medical College, Philadelphia, Pennsylvania
3 shared publicationsYing Liu
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Zhongshan Road 222, PO Box 116011, Dalian, Liaoning China
3 shared publications- Yunlong Xia
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China
3 shared publications - Binhao Wang
Arrhythmia Center, Ningbo First Hospital, Ningbo 315000, China
2 shared publications - Haixu Yu
Department of Cardiology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
2 shared publications Jinqiu Liu
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
2 shared publications
Latest Publications
- Open Access
- 14 February 2020
- Published by Springer Nature in Cardio-Oncology
- Vol. 6 (1) , 1-7
Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study
Our recent study has revealed that many hospitalized patients with acquired long QT syndrome (ALQTS) are cancer patients. This study aims to determine the risk factors and outcomes of hospitalized cancer patients with ALQTS. We performed a matched case-control study within a cohort of 10,180 cancer patients hospitalized between September 2013 and April 2016. Among them, 150 patients defined as having severe ALQTS with a markedly prolonged QT interval (QTc ≥ 500 ms) were compared with 293 age-, sex- and cancer-type-matched controls (non-ALQTS). Death as the endpoint was followed for up to 2 years. Cox regression and Kaplan-Meier survival analyses were performed to assess the effects of particular clinical variables on all-cause mortality. Multivariate logistic regression was performed to calculate odds ratios (OR) for various predictors of QT prolongation. The mortality was significantly higher in ALQTS group (63.3% vs. 33.4%). Hypertension, hypokalemia, hypocalcemia, QT-prolonging drugs, infection, anemia, anti-microtubule agents were contributing factors to ALQTS. Renal insufficiency, male gender and hypokalemia were found to be independent risk factors for all-cause mortality in ALQTS group. Markedly prolonged QT interval was seen in 1.5% of hospitalized cancer patients. The all-cause mortality was high in cancer patients with severe ALQTS.
- 14 February 2020
- Published by Springer Nature in Cardio-Oncology
- Vol. 6 (1) , 1-7
Open AccessHospitalized cancer patients with acquired long QT syndrome-a matched case-control study
Our recent study has revealed that many hospitalized patients with acquired long QT syndrome (ALQTS) are cancer patients. This study aims to determine the risk factors and outcomes of hospitalized cancer patients with ALQTS. We performed a matched case-control study within a cohort of 10,180 cancer patients hospitalized between September 2013 and April 2016. Among them, 150 patients defined as having severe ALQTS with a markedly prolonged QT interval (QTc ≥ 500 ms) were compared with 293 age-, sex- and cancer-type-matched controls (non-ALQTS). Death as the endpoint was followed for up to 2 years. Cox regression and Kaplan-Meier survival analyses were performed to assess the effects of particular clinical variables on all-cause mortality. Multivariate logistic regression was performed to calculate odds ratios (OR) for various predictors of QT prolongation. The mortality was significantly higher in ALQTS group (63.3% vs. 33.4%). Hypertension, hypokalemia, hypocalcemia, QT-prolonging drugs, infection, anemia, anti-microtubule agents were contributing factors to ALQTS. Renal insufficiency, male gender and hypokalemia were found to be independent risk factors for all-cause mortality in ALQTS group. Markedly prolonged QT interval was seen in 1.5% of hospitalized cancer patients. The all-cause mortality was high in cancer patients with severe ALQTS.
- 1 November 2018
- Published by Elsevier in Journal of Electrocardiology
- Vol. 51 (6) , 1061-1065
The role of mexiletine in the management of long QT syndrome
- 1 November 2018
- Published by Elsevier in Journal of Electrocardiology
- Vol. 51 (6) , 1061-1065
The role of mexiletine in the management of long QT syndrome
- 1 July 2017
- Published by Elsevier in Heart Rhythm
- Vol. 14 (7) , 974-978
Acquired long QT syndrome in hospitalized patients
- 1 July 2017
- Published by Elsevier in Heart Rhythm
- Vol. 14 (7) , 974-978
Acquired long QT syndrome in hospitalized patients
- 18 April 2017
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 28 (6) , 684-689
A New Formula for Estimating the True QT Interval in Left Bundle Branch Block
A New QT Formula for LBBB: Introduction: QT prolongation is an independent risk factor for cardiac mortality. Left bundle branch block (LBBB) is more common in patients as they age. Widening of the QRS in LBBB causes false QT prolongation and thus makes true QT assessment difficult. We aimed to develop a simple formula to achieve a good estimate of the QT interval in the presence of LBBB.Methods and Results: To determine the effect of QRS duration on the QT interval, QRS and QT were measured in sinus rhythm and during right ventricular apical pacing in 62 patients (age 55 ± 11 years, 60% male) undergoing electrophysiology studies. A QT formula for LBBB (QT‐LBBB) was derived based on the effect of increased QRSLBBB on QTLBBB. The predictive accuracy of the QT‐LBBB formula was then tested in 22 patients (age 66 ± 13 years, 64% male) with intermittent LBBB with comparisons to prior QT formulae and JT index. On average, the net increase in QRSLBBB constituted 92% of the net increase in QTLBBB. A new formula, QT‐LBBB = QTLBBB – (0.86 * QRSLBBB – 71), which takes the net increase in QRSLBBB into account, best predicted the QT interval with heart rate corrected QTc in the test set of LBBB ECGs when compared to the baseline value and prior formulae.Conclusion: The QT‐LBBB formula developed in this study best estimates the true QT interval in the presence of LBBB. It is simple and therefore can be easily utilized in clinical practice.
- 18 April 2017
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 28 (6) , 684-689
A New Formula for Estimating the True QT Interval in Left Bundle Branch Block
A New QT Formula for LBBB: Introduction: QT prolongation is an independent risk factor for cardiac mortality. Left bundle branch block (LBBB) is more common in patients as they age. Widening of the QRS in LBBB causes false QT prolongation and thus makes true QT assessment difficult. We aimed to develop a simple formula to achieve a good estimate of the QT interval in the presence of LBBB.Methods and Results: To determine the effect of QRS duration on the QT interval, QRS and QT were measured in sinus rhythm and during right ventricular apical pacing in 62 patients (age 55 ± 11 years, 60% male) undergoing electrophysiology studies. A QT formula for LBBB (QT‐LBBB) was derived based on the effect of increased QRSLBBB on QTLBBB. The predictive accuracy of the QT‐LBBB formula was then tested in 22 patients (age 66 ± 13 years, 64% male) with intermittent LBBB with comparisons to prior QT formulae and JT index. On average, the net increase in QRSLBBB constituted 92% of the net increase in QTLBBB. A new formula, QT‐LBBB = QTLBBB – (0.86 * QRSLBBB – 71), which takes the net increase in QRSLBBB into account, best predicted the QT interval with heart rate corrected QTc in the test set of LBBB ECGs when compared to the baseline value and prior formulae.Conclusion: The QT‐LBBB formula developed in this study best estimates the true QT interval in the presence of LBBB. It is simple and therefore can be easily utilized in clinical practice.
- Open Access
- 1 September 2014
- Published by Elsevier in IJC Heart & Vessels
- Vol. 4, 122-128
Long QT syndrome, cardiovascular anomaly and findings in ECG-guided genetic testing
- 1 September 2014
- Published by Elsevier in IJC Heart & Vessels
- Vol. 4, 122-128
Open AccessLong QT syndrome, cardiovascular anomaly and findings in ECG-guided genetic testing
- Open Access
- 31 May 2014
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 10 (3) , 237-245
The Electrocardiographic Manifestations of Arrhythmogenic Right Ventricular Dysplasia
The ECG is abnormal in most patients with arrhythmogenic right ventricular dysplasia (ARVD). Right ventricular parietal block, reduced QRS amplitude, epsilon wave, T wave inversion in V1-3 and ventricular tachycardia in the morphology of left bundle branch block are the characteristic changes that reflect the underlying genetic predetermined pathology and pathoelectrophysiology. Recognizing the characteristic ECG changes in ARVD will be of help in making a correct diagnosis of this rare disease.
- 31 May 2014
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 10 (3) , 237-245
Open AccessThe Electrocardiographic Manifestations of Arrhythmogenic Right Ventricular Dysplasia
The ECG is abnormal in most patients with arrhythmogenic right ventricular dysplasia (ARVD). Right ventricular parietal block, reduced QRS amplitude, epsilon wave, T wave inversion in V1-3 and ventricular tachycardia in the morphology of left bundle branch block are the characteristic changes that reflect the underlying genetic predetermined pathology and pathoelectrophysiology. Recognizing the characteristic ECG changes in ARVD will be of help in making a correct diagnosis of this rare disease.
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 6 (8) , 764-70
Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?
Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in the young, particularly among athletes. Identifying high risk individuals is very important for SCD prevention. The purpose of this review is to stress that noninvasive diagnostic testing is important for risk assessment. Extreme left ventricular hypertrophy and documented ventricular tachycardia and fibrillation increase the risk of SCD. Fragmented QRS and T wave inversion in multiple leads are more common in high risk patients. Cardiac magnetic resonance imaging provides complete visualization of the left ventricular chamber, allowing precise localization of the distribution of hypertrophy and measurement of wall thickness and cardiac mass. Moreover, with late gadolinium enhancement, patchy myocardial fibrosis within the area of hypertrophy can be detected, which is also helpful in risk stratification. Genetic testing is encouraged in all cases, especially in those with a family history of HCM and SCD.
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Cardiology
- Vol. 6 (8) , 764-70
Open AccessHypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?
Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in the young, particularly among athletes. Identifying high risk individuals is very important for SCD prevention. The purpose of this review is to stress that noninvasive diagnostic testing is important for risk assessment. Extreme left ventricular hypertrophy and documented ventricular tachycardia and fibrillation increase the risk of SCD. Fragmented QRS and T wave inversion in multiple leads are more common in high risk patients. Cardiac magnetic resonance imaging provides complete visualization of the left ventricular chamber, allowing precise localization of the distribution of hypertrophy and measurement of wall thickness and cardiac mass. Moreover, with late gadolinium enhancement, patchy myocardial fibrosis within the area of hypertrophy can be detected, which is also helpful in risk stratification. Genetic testing is encouraged in all cases, especially in those with a family history of HCM and SCD.